<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>How Well Do LLMs Understand Drug Mechanisms? A Knowledge + Reasoning Evaluation Dataset - Health AI Hub</title>
    <meta name="description" content="This paper introduces a novel dataset to rigorously evaluate Large Language Models' (LLMs) comprehension of drug mechanisms, focusing on both factual recall and">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>How Well Do LLMs Understand Drug Mechanisms? A Knowledge + Reasoning Evaluation Dataset</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.06418v1" target="_blank">2511.06418v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-09
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Sunil Mohan, Theofanis Karaletsos
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.CL
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.06418v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.06418v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a novel dataset to rigorously evaluate Large Language Models' (LLMs) comprehension of drug mechanisms, focusing on both factual recall and counterfactual reasoning in unseen situations. The study reveals that o4-mini and Qwen3-4B-thinking models demonstrate superior performance among tested LLMs, and highlights that open-world reasoning and counterfactuals affecting internal links of drug mechanism chains pose significantly greater challenges.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Accurate and deep understanding of drug mechanisms by LLMs is critical for accelerating drug discovery, identifying new therapeutic uses for existing drugs (repurposing), and tailoring treatments to individual patient profiles in personalized medicine, ultimately leading to more effective and safer healthcare interventions.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This research evaluates the foundational capabilities of Large Language Models (LLMs) to understand and reason about drug mechanisms. This is critical for developing AI applications in health, such as: identifying new drug candidates or repurposing existing drugs; assisting in personalized medicine by predicting drug efficacy and suitability for individual patients; and potentially aiding in clinical decision support systems by providing insights into drug actions and interactions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>LLMs require deep understanding of drug mechanisms, beyond just factual knowledge, for applications in drug development, repurposing, and personalized medicine.</li>
                    
                    <li>Drug mechanisms are conceptualized as directed chains of interactions between biomedical entities, linking a drug to its target disease.</li>
                    
                    <li>A new dataset was developed to evaluate LLMs on factual knowledge of known drug mechanisms and their ability to reason about novel, counterfactual scenarios.</li>
                    
                    <li>The o4-mini model from OpenAI outperformed 4o, o3, and o3-mini models in understanding drug mechanisms and reasoning.</li>
                    
                    <li>The Qwen3-4B-thinking model closely matched o4-mini's performance and even surpassed it in certain evaluations, demonstrating strong capabilities from a smaller, open model.</li>
                    
                    <li>Open-world reasoning tasks, which necessitate the LLM to recall relevant knowledge, are substantially more challenging than closed-world tasks where necessary facts are provided.</li>
                    
                    <li>Counterfactuals that perturb internal links within a drug's mechanism-of-action chain present a much harder reasoning task for LLMs compared to those affecting the initial link from the drug itself.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study's methodology centers on the creation of a specialized dataset designed to test LLMs on two dimensions: factual knowledge of established drug mechanisms and the ability to reason under counterfactual conditions. These counterfactuals represent novel situations unlikely to be present in training data. The dataset evaluates LLMs on their capacity to infer the utility of a drug for a disease by composing the effects of interactions in a candidate mechanism chain. Performance comparisons were then made across several prominent LLMs (OpenAI's o4-mini, 4o, o3, o3-mini, and Qwen3-4B-thinking) under both open-world (knowledge recall required) and closed-world (knowledge provided) settings, and by varying the complexity of counterfactuals.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The o4-mini model demonstrated superior understanding and reasoning capabilities compared to other OpenAI models tested (4o, o3, o3-mini). Notably, the smaller Qwen3-4B-thinking model achieved comparable or even superior performance to o4-mini. The research revealed that open-world reasoning tasks, requiring LLM knowledge recall, are significantly harder than closed-world tasks. Furthermore, counterfactual scenarios altering internal links within a drug's mechanism chain posed a greater challenge for LLMs than those affecting the initial drug-target interaction.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This research provides a benchmark for developing LLMs capable of more sophisticated biomedical reasoning, which could revolutionize drug discovery by predicting novel drug-disease relationships, streamlining drug repurposing efforts, and informing personalized treatment strategies by understanding individual variability in drug response based on detailed mechanism insights. Improved LLM performance in this area could lead to faster identification of promising therapeutic candidates and more precise, individualized medicine.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations of the study itself. However, it implicitly highlights the current limitations of LLMs in fully comprehending and reasoning about complex drug mechanisms, particularly in open-world settings and when faced with nuanced counterfactual changes to internal biological pathways.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly state future research directions. However, the findings implicitly suggest future work could involve enhancing LLM architectures and training methodologies to improve open-world knowledge recall and their ability to handle complex, multi-step counterfactual reasoning within biological pathways, particularly concerning internal mechanistic links. Further benchmarking with a wider range of LLMs and more diverse drug mechanisms would also be a logical next step.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Personalized Medicine</span>
                    
                    <span class="tag">Therapeutics</span>
                    
                    <span class="tag">Biomedical Research</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">LLMs</span>
                    
                    <span class="tag tag-keyword">Drug Mechanisms</span>
                    
                    <span class="tag tag-keyword">Counterfactual Reasoning</span>
                    
                    <span class="tag tag-keyword">Drug Development</span>
                    
                    <span class="tag tag-keyword">Personalized Medicine</span>
                    
                    <span class="tag tag-keyword">Knowledge Evaluation</span>
                    
                    <span class="tag tag-keyword">Biomedical Reasoning</span>
                    
                    <span class="tag tag-keyword">Pharmacology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Two scientific fields showing increasing interest in pre-trained large
language models (LLMs) are drug development / repurposing, and personalized
medicine. For both, LLMs have to demonstrate factual knowledge as well as a
deep understanding of drug mechanisms, so they can recall and reason about
relevant knowledge in novel situations. Drug mechanisms of action are described
as a series of interactions between biomedical entities, which interlink into
one or more chains directed from the drug to the targeted disease. Composing
the effects of the interactions in a candidate chain leads to an inference
about whether the drug might be useful or not for that disease. We introduce a
dataset that evaluates LLMs on both factual knowledge of known mechanisms, and
their ability to reason about them under novel situations, presented as
counterfactuals that the models are unlikely to have seen during training.
Using this dataset, we show that o4-mini outperforms the 4o, o3, and o3-mini
models from OpenAI, and the recent small Qwen3-4B-thinking model closely
matches o4-mini's performance, even outperforming it in some cases. We
demonstrate that the open world setting for reasoning tasks, which requires the
model to recall relevant knowledge, is more challenging than the closed world
setting where the needed factual knowledge is provided. We also show that
counterfactuals affecting internal links in the reasoning chain present a much
harder task than those affecting a link from the drug mentioned in the prompt.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>An earlier version of this paper appears in IEEE FLLM 2025. GitHub:
  https://github.com/czi-ai/DrugMechCounterfactuals</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>